Back
 IJCM  Vol.11 No.12 , December 2020
Patterns and Changes in the Treatment of Patients with Type II Diabetes Mellitus in Egypt: The DISCOVER Program
Abstract: The DISCOVER study is a three-year, non-interventional prospective study conducted in 37 countries, including Egypt, to assess the treatment patterns and outcomes in patients with type 2 diabetes mellitus initiating a second-line antidiabetic therapy (add-on or switch). In this report of the Egyptian cohort of DISCOVER, baseline data were collected according to routine clinical practice at 38 study sites, using a standardized electronic case report form, in the period from December-2014 to November-2019. We enrolled 583 patients (mean age: 52.9 ± 9.8 years and median duration since diagnosis: median 36.5, IQR 18.1, 70.4 months). The mean HbA1c value at baseline was 8.6 ± 1.4%, indicating poor glycemic control. The most commonly prescribed first-line medications were metformin or sulfonylurea monotherapy. For second line-therapy, the majority of patients switched to dual therapy with metformin plus sulfonylureas or DPP-4 inhibitors. Fewer patients switched to triple therapy, treatment by four or more medications, or insulin treatment (15, 12, and 35 patients, respectively). The most commonly cited reasons for switching to second-line therapy were lack of efficacy, weight gain, hypoglycemic events, and side effects (549, 54, 25, and 21 patients, respectively). The set treatment target of enrolled patients at the initiation of second-line therapy was an HbA1c level of 6.9%. Follow-up data will assess the outcomes of such changes in the Egyptian population.
Cite this paper: Shelbaya, S. , Khattab, M. , Abdallah, K. , Ghanem, Y. , El Hefnawy, H. , Shaltout, E. , Roshdy, E. and Issak, E. (2020) Patterns and Changes in the Treatment of Patients with Type II Diabetes Mellitus in Egypt: The DISCOVER Program. International Journal of Clinical Medicine, 11, 731-742. doi: 10.4236/ijcm.2020.1112054.
References

[1]   American Diabetes Association (2015) Diabetes Statistics.
http://www.diabetes.org

[2]   US Center of Disease Prevention and Control (2014) National Diabetes Statistics Report.
http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html

[3]   Hegazi, R., El-Gamal, M., Abdel-Hady, N. and Hamdy, O. (2015) Epidemiology of and Risk Factors for Type 2 Diabetes in Egypt. Annals of Global Health, 81, 814-820.
https://doi.org/10.1016/j.aogh.2015.12.011

[4]   Whiting, D.R., Guariguata, L., Weil, C. and Shaw, J. (2011) IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030. Diabetes Research and Clinical Practice, 94, 311-321.
https://doi.org/10.1016/j.diabres.2011.10.029

[5]   Bos, M. and Agyemang, C. (2013) Prevalence and Complications of Diabetes Mellitus in Northern Africa, a Systematic Review. BMC Public Health, 13, Article No. 387.
https://doi.org/10.1186/1471-2458-13-387

[6]   El Husseny, M.W.A., Mamdouh, M., Shaban, S., Ibrahim Abushouk, A., Zaki, M.M.M., Ahmed, O.M. and Abdel-Daim, M.M. (2017) Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity. Journal of Diabetes Research, 2017, Article ID: 8095926.
https://doi.org/10.1155/2017/8095926

[7]   Marathe, P.H., Gao, H.X. and Close, K.L. (2017) American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of Diabetes, 9, 320-324.
https://doi.org/10.1111/1753-0407.12524

[8]   Handelsman, Y., Bloomgarden, Z.T., Grunberger, G., Umpierrez, G., Zimmerman, R.S., Bailey, T.S. and Blonde, L. (2015) American Association of Clinical Endocrinologists and American College of Endocrinology—Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan—2015. Endocrine Practice, 21, 1-87.
https://doi.org/10.4158/EP15672.GLSUPPL

[9]   The ADVANCE Collaborative Group (2008) Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 358, 2560-2572.
https://doi.org/10.1056/NEJMoa0802987

[10]   Lazar, H.L., Chipkin, S.R., Fitzgerald, C.A., Bao, Y.S., Cabral, H. and Apstein, C.S. (2004) Tight Glycemic Control in Diabetic Coronary Artery Bypass Graft Patients Improves Perioperative Outcomes and Decreases Recurrent Ischemic Events. Circulation, 109, 1497-1502.
https://doi.org/10.1161/01.CIR.0000121747.71054.79

[11]   Shams, M.E. and Barakat, E.A. (2010) Measuring the Rate of Therapeutic Adherence among Outpatients with T2DM in Egypt. Saudi Pharmaceutical Journal, 18, 225-232.
https://doi.org/10.1016/j.jsps.2010.07.004

[12]   Koura, M.R., Khairy, A.E., Abdel-Aal, N.M., Mohamed, H.F., Amin, G.A. and Sabra, A.Y. (2001) The Role of Primary Health Care in Patient Education for Diabetes Control. The Journal of the Egyptian Public Health Association, 76, 241-264.

[13]   Ji, L.N., Bonnet, F., Charbonnel, B., Gomes, M.B., Kosiborod, M., Khunti, K., et al. (2017) Towards an Improved Global Understanding of Treatment and Outcomes in People with Type 2 Diabetes: Rationale and Methods of the DISCOVER Observational Study Program. Journal of Diabetes and Its Complications, 31, 1188-1196.
https://doi.org/10.1016/j.jdiacomp.2017.03.011

[14]   Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M.E., Colagiuri, S., et al. (2012) Association of HbA1c Levels with Vascular Complications and Death in Patients with Type 2 Diabetes: Evidence of Glycaemic Thresholds. Diabetologia, 55, 636-643.
https://doi.org/10.1007/s00125-011-2404-1

[15]   O’sullivan, C., Hynes, N., Mahendran, B., Andrews, E.J., Avalos, G., Tawfik, S., Lowery, A., Sultan, S. (2006) Haemoglobin A1c (HbA1C) in Non-Diabetic and Diabetic Vascular Patients. Is HbA1C an Independent Risk Factor and Predictor of Adverse Outcome? European Journal of Vascular and Endovascular Surgery, 32, 188-197.
https://doi.org/10.1016/j.ejvs.2006.01.011

[16]   O’Hare, J.P., Miller-Jones, D., Hanif, W., Hicks, D., Evans, M., Leslie, D., Bain, S.C. and Barnett, A.H. (2015) The New NICE Guidelines for Type 2 Diabetes—A Critical Analysis. British Journal of Diabetes, 15, 3-7.
https://doi.org/10.15277/bjdvd.2015.006

[17]   Levin, P.A., Wei, W.H., Zhou, S., Xie, L. and Baser, O. (2014) Outcomes and Treatment Patterns of Adding a Third Agent to 2 OADs in Patients with Type 2 Diabetes. Journal of Managed Care Pharmacy, 20, 501-512.
https://doi.org/10.18553/jmcp.2014.20.5.501

[18]   Gómez-Peralta, F., Carramiñana-Barrera, F., Félix-Redondo, F.J. and Fraile-Gómez, J. (2012) Glycaemic Control in Patients with Type 2 Diabetes Switching from Premixed Insulin to Long-Acting Basal Insulin Analogue Plus Oral Antidiabetic Drugs: An Observational Study. International Journal of Clinical Practice, 66, 959-968.
https://doi.org/10.1111/j.1742-1241.2012.03000.x

[19]   Plat, A., Penning-van Beest, F., Kessabi, S., Groot, M. and Herings, R. (2009) Change of Initial Oral Antidiabetic Therapy in Type 2 Diabetic Patients. Pharmacy World & Science, 31, Article No. 622.
https://doi.org/10.1007/s11096-009-9321-0

[20]   Asche, C.V., McAdam-Marx, C., Shane-McWhorter, L., Sheng, X. and Plauschinat, C.A. (2008) Association between Oral Antidiabetic Use, Adverse Events and Outcomes in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 10, 638-645.
https://doi.org/10.1111/j.1463-1326.2007.00758.x

 
 
Top